Introduction
Cerebral ischemia overproduces free radicals, which are believed to contribute to neuronal cell injury during cerebral infarction (1, 2) . Therefore, it was suggested that reducing free radicals would be an effective neuroprotective treatment in cerebral infarction. The free radical scavenger, edaravone, is the first neuroprotective agent approved by the Japanese Ministry of Health and Welfare for clinical use. Although a randomized, placebo-controlled, double-blind study conducted at multiple centers in Japan showed the efficacy of edaravone in acute cerebral infarction (3) , the clinical trials are few (4) (5) (6) (9) . Although there were no significant differences in NIHSS on admission and NIHSS at discharge in the two groups, NIHSS on admission was slightly larger and NIHSS at discharge was smaller in the edaravone group. Therefore, the reduction in the NIHSS during hospitalization could be significantly larger in the edaravone group. We considered that the reduction in the NIHSS during hospitalization showed the degree of improvement, and it was better for the assessment of the efficacy of edaravone.
Discussion

Previous reports have shown the efficacy of edaravone in acute ischemic stroke, which includes lacunar infarction (3-6). In the present study, we demonstrated that the free radical scavenger, edaravone, improved the outcomes of patients with acute lacunar infarction, especially motor palsy of the face and upper and lower extremities, whatever the conventional therapies performed concomitantly. This effect seems a significant advantage of edaravone, because motor paresis has more effects on activities of daily living than other typical neurological symptoms of lacunar infarction such as pure sensory stroke and ataxic hemiparesis
The pathomechanism of the favorable effect of a free radical scavenger in lacunar infarct is considered to be as T a b l e 1 . Cl i n i c a l Ch a r a c t e r i s t i c s a n d Ou t c o me s o f P a t i e n t Aspirin + thienopyridines 0 2
Mean NIHSS on admission ± SD 2.2 ± 1.0 2.0 ± 1.3
Mean time to treatment ± SD (h) 9.2 ± 5.8 9.8 ± 7.0
Mean duration of hospitalization ± SD (days) 9.4 ± 2.6 8.5 ± 2.7
Mean NIHSS at discharge ± SD 0.7 ± 0. (10, 11) , tissue injury (12) , delayed neuronal death (13) , and vascular endothelial cell injury after ischemia (14) . (16, 17) .
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